These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8799494)

  • 21. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
    Siegsmund MJ; Kreukler C; Steidler A; Nebe T; Köhrmann KU; Alken P
    Urol Res; 1997; 25(1):35-41. PubMed ID: 9079744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dexniguldipine-HCl is a potent allosteric inhibitor of [3H]vinblastine binding to P-glycoprotein of CCRF ADR 5000 cells.
    Malkhandi J; Ferry DR; Boer R; Gekeler V; Ise W; Kerr DJ
    Eur J Pharmacol; 1994 Dec; 288(1):105-14. PubMed ID: 7705462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance.
    Léonce S; Pierré A; Anstett M; Pérez V; Genton A; Bizzari JP; Atassi G
    Biochem Pharmacol; 1992 Nov; 44(9):1707-15. PubMed ID: 1360210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo.
    Miyamoto K; Inoko K; Wakusawa S; Kajita S; Hasegawa T; Takagi K; Koyama M
    Cancer Res; 1993 Apr; 53(7):1555-9. PubMed ID: 8095855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutathione-S-transferase P-form dependent chlorambucil resistance in Yoshida rat ascites hepatoma cell lines.
    Miyamoto K; Wakabayashi D; Minamino T; Nomura M
    Cancer Lett; 1994 Apr; 78(1-3):77-83. PubMed ID: 7910111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reversal of multidrug resistance in vivo by dietary administration of the phytochemical indole-3-carbinol.
    Christensen JG; LeBlanc GA
    Cancer Res; 1996 Feb; 56(3):574-81. PubMed ID: 8564974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Saturable function of P-glycoprotein as a drug-efflux pump in multidrug-resistant tumour cells.
    Miyamoto KI; Koga-Takeda K; Koga K; Ohshima T; Nomura M
    J Pharm Pharmacol; 1996 May; 48(5):522-5. PubMed ID: 8799879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells.
    Ido M; Nagao Y; Higashigawa M; Shibata T; Taniguchi K; Hamazaki M; Sakurai M
    Br J Cancer; 1991 Dec; 64(6):1103-7. PubMed ID: 1684908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circumvention of multidrug resistance in P388 murine leukemia cells by a novel inhibitor of cyclic AMP-dependent protein kinase, H-87.
    Miyamoto K; Wakusawa S; Nakamura S; Koshiura R; Otsuka K; Naito K; Hagiwara M; Hidaka H
    Cancer Lett; 1990 May; 51(1):37-42. PubMed ID: 2337896
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Different effects of FK317 on multidrug-resistant tumor in vivo and in vitro.
    Naoe Y; Inami M; Takagaki S; Matsumoto S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
    Jpn J Cancer Res; 1998 Oct; 89(10):1047-54. PubMed ID: 9849584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel dithiane analogues of tiapamil with high activity to overcome multidrug resistance in vitro.
    Eliason JF; Ramuz H; Yoshikubo T; Ishikawa T; Yamamoto T; Tsuruo T
    Biochem Pharmacol; 1995 Jul; 50(2):187-96. PubMed ID: 7632162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein substrates and antagonists cluster into two distinct groups.
    Scala S; Akhmed N; Rao US; Paull K; Lan LB; Dickstein B; Lee JS; Elgemeie GH; Stein WD; Bates SE
    Mol Pharmacol; 1997 Jun; 51(6):1024-33. PubMed ID: 9187269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
    Germann UA; Shlyakhter D; Mason VS; Zelle RE; Duffy JP; Galullo V; Armistead DM; Saunders JO; Boger J; Harding MW
    Anticancer Drugs; 1997 Feb; 8(2):125-40. PubMed ID: 9073309
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein mediated resistance to 5'-nor-anhydro-vinblastine (Navelbine).
    Adams DJ; Knick VC
    Invest New Drugs; 1995; 13(1):13-21. PubMed ID: 7499103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo cisplatin resistance of rat ascites hepatoma AH66.
    Minamino T; Nomura M; Tamai M; Moritani S; Ohshima T; Miyamoto K
    Cancer Lett; 1996 Nov; 108(2):153-6. PubMed ID: 8973588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Localization of the 1,4-dihydropyridine drug acceptor of P-glycoprotein to a cytoplasmic domain using a permanently charged derivative N-methyl dexniguldipine.
    Ferry D; Boer R; Callaghan R; Ulrich WR
    Int J Clin Pharmacol Ther; 2000 Mar; 38(3):130-40. PubMed ID: 10739116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
    Dale IL; Tuffley W; Callaghan R; Holmes JA; Martin K; Luscombe M; Mistry P; Ryder H; Stewart AJ; Charlton P; Twentyman PR; Bevan P
    Br J Cancer; 1998 Oct; 78(7):885-92. PubMed ID: 9764579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celastraceae sesquiterpenes as a new class of modulators that bind specifically to human P-glycoprotein and reverse cellular multidrug resistance.
    Muñoz-Martínez F; Lu P; Cortés-Selva F; Pérez-Victoria JM; Jiménez IA; Ravelo AG; Sharom FJ; Gamarro F; Castanys S
    Cancer Res; 2004 Oct; 64(19):7130-8. PubMed ID: 15466210
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between the inhibition of azidopine binding to P-glycoprotein by MDR modulators and their efficiency in restoring doxorubicin intracellular accumulation.
    Hu YP; Chapey C; Robert J
    Cancer Lett; 1996 Dec; 109(1-2):203-9. PubMed ID: 9020922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.